# An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO

> **NCT00379795** · NA · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 853 (actual)

## Conditions studied

- Choroidal Neovascularization, Age-related Macular Degeneration

## Interventions

- **DRUG:** Ranibizumab 0.5 mg

## Key facts

- **NCT ID:** NCT00379795
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 853 (ACTUAL)
- **Last updated:** 2017-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00379795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00379795, "An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT00379795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*